Portal de Periódicos da CAPES

Trimetazidine: Experimental and Clinical Update Review

1998; Wiley; Volume: 16; Issue: 4 Linguagem: Italiano

10.1111/j.1527-3466.1998.tb00364.x

1527-3466

E Albengres, Jean‐Paul Tillement, Hervé Le Louët, Didier Morin,

Cardiac pacing and defibrillation studies

Cardiovascular Drug ReviewsVolume 16, Issue 4 p. 359-390 Free Access Trimetazidine: Experimental and Clinical Update Review Edith Albengres, Edith Albengres Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this authorJean-Paul Tillement, Corresponding Author Jean-Paul Tillement Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceAddress correspondence and reprint requests to Prof. J.-P. Tillement, Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, 8 Rue du Général Sarrail F-94 010 Creteil, France.Search for more papers by this authorHervé Le Louet, Hervé Le Louet Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this authorDidier Morin, Didier Morin Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this author Edith Albengres, Edith Albengres Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this authorJean-Paul Tillement, Corresponding Author Jean-Paul Tillement Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceAddress correspondence and reprint requests to Prof. J.-P. Tillement, Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, 8 Rue du Général Sarrail F-94 010 Creteil, France.Search for more papers by this authorHervé Le Louet, Hervé Le Louet Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this authorDidier Morin, Didier Morin Service Hospitalo-Universitaire de Pharmacologie, Faculté de Médecine Paris XII, FranceSearch for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1998.tb00364.xCitations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Abadie C, Ben Baouali A, Nadeau R, Rochette L. Myocardial dysfunction induced by electrolysis as a source of oxygen free radicals: Effect of trimetazidine and serum albumin. 2 J Mol Cell Cardiol 1993; 25(suppl. 4): S40. 2 Albengres E, Tillement JP, D'Athis P, Salducci D, Chauvet-Monges AM, Crevat A. Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models. Fund Clin Pharmacol 1996; 10: 264– 268. 3 Ancerewicz J, Migliavacca E, Carrupt PA, et al. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radic Biol Med 1998; 11: 113– 120. 4 Aubert A, Bernard C, Clauser P, Harpey C, Vaudry H. Effect of phenazine methosulfate on electrophysiological activity of the semicircular canal: Antioxidant properties of trimetazidine. Eur J Pharmacol 1989; 174: 215– 225. 5 Aubert A, Bernard C, Clauser P, Harpey C, Vaudry H. The antiischemic drug, trimetazidine, prevents the deleterious effects of oxygen free radicals on the inner ear. Drugs Today 1990; 26(suppl. 13): 33– 41. 6 Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the anti-ischemic agent trimetadizine. J Cardiovasc Pharmacol 1993; 21: 128– 135. 7 Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993; 7: 149– 157. 8 Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Trimetazidine reduces myocardial infarct size, relative to area at risk, after temporary coronary artery occlusion in the rabbit. Br J Pharmacol 1992; 107(Suppl.): 265 p. 9 Boucher FR, Hearse DJ, Opie LH. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 1994; 24: 45– 49. 10 Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207– 212. 11 Camilleri JP, Joseph D. Effects of trimetazidine on experimental reperfused infarction in the rat. Eur Heart J 1988; 9(suppl. 1): 217. 12 Catroux P, Cambar J, Benchekroun N, Robert J, Clauser P, Harpey C. Antilipoperoxidant effect of trimetazidine in post-ischaemic acute renal failure in the rat. In: Antioxidants in therapy and preventive medicine. New York : Plenum Press. 1990; I: 383– 388. 13 Catroux P, Dorian C, Harpey C, Cambar J. Mise en évidence de l'effet protecteur de la trimetazidine vis-à-vis de l'enzymurie induite par clampage du pédicule rénal chez le rat. Néphrologie 1986; 7: 124. 14 Cazals Y, Wu ZY, Horner K. Alterations of auditory nerve response by hypoxia in normal and hydropic ears of awake guinea pig. Hearing Res 1994; 77: 177– 182. 15 Coyas A. Assessment of trimetazidine activity in cochleo-vestibular disorders of ischemic origin. A crossover, placebo-controlled trial. Drugs Today 1990; 26(suppl. 8): 97– 102. 16 Creagh T, Lanigan D, Dolan J, Tormey W, Walshe JJ, Bouchier-Hayes D. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine. J Urol 1993; 149: 915– 917. 17 Creagh T, Lanigan D, Murphy D, McLean P, Bouchier-Hayes D. Amelioration of cyclosporin-enhanced ischaemic renal failure with trimetazidine. Br J Surg 1991; 78: 1493– 1494. 18 Cruz C, Zaoui A, Ayoub S, Harpey C, Goupit P, Younès A. Altérations des myocytes isolés des ventricules de coeur de rat adulte: Protection par la Trimétazidine. Concours Med 1987; 109(suppl. 36): 3470– 3475. 19 D'Alché P, Clauser P, Morel M, Gauthier V. Assessment with potential mapping of the cardiac protective effect of a drug. Example of trimetazidine. J Pharmacol Methods 1991; 26: 43– 51. 20 D'Hahan N, Robert K, Maixent JM, Morel JE. Cellular and biochemical aspects of cardioprotection by trimetazidine in the cardiomyopathic Syrian hamster. J Mol Cell Cardiol 1997; 76: 31B– 37B. 21 Dalla Volta S, Maragiino G, Delia Valentina B, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double blind, cross-over study. Cardiovasc Drugs Ther 1990; 4(suppl. 4): 853– 860. 22 David-Dufillo M, Do T, Devynck MA, van Brussel-Millanvoye E. Action of trimetazidine on cytosolic Ca2+ concentration and pH in hypoxic and reoxygenated cardiac myocytes. J Mol Cell Cardiol 1997; 29: A77. 23 Delbarre B, Delbarre G, Calinon F. Action of trimetazidine in retina of gerbils after ischemia reperfusion insult: Determination of OH, amino acids, and electroretinogram. Ann NY Acad Sci 1994; 738: 334– 340. 24 Demaison L, Fantini E, Sentex E, Grynberg A, Athias P. Trimetazidine: In vitro influence on heart mitochondrial function. Am J Cardiol 1995; 76: 31B– 37B. 25 Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994: 37: 279– 288. 26 Didier JP, Roux J, Violot D, Justrabo E. Les effets de la trimétazidine sur le coeur isolé perfusé de rat en hypoxie: Étude hémodynamique et histologique. Gaz Med Fr 1984; 91(suppl. 26): 28– 34. 27 Doly M. Rétine et radicaux libres. Ophtalmol Fr 1988; (n° spécial): 98– 105. 28 Drake-Holland AJ, Belcher PR, Hynd JW, Noble MIM. Infarct size in rabbits: A modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol 1993; 88: 250– 258. 29 El Banani H, Bernard M, Cozzone P, James F, Feuvray D. Effects of trimetazidine on ionic and metabolic during ischaemia and reperfusion. J Mol Cell Cardiol 1997; 29: Fr59. 30 Elimadi A, Morin D, Sapena R, Chauvet-Monges AM, Crevat A, Tillement JP. Comparison of the effects of cyclosporine A and trimetazidine on Ca2+-dependent mitochondrial swelling. Fund Clin Pharmacol 1997; 11: 440– 447. 31 Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemiareperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 1998; 286: 23– 28. 32 Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992; 33: 486– 491. 33 Fantini E, Athias P, Demaison L, Grynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from rats. Fund Clin Pharmacol 1997; 11: 427– 439. 34 Fantini E, Athias P, Grynberg A. Trimetazidine: Functional and biochemical protection of isolated rat ventricular myocytes during in vitro simulated ischemia. J Mol Cell Cardiol 1993; 25(suppl. 1): S61. 35 Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949– 958. 36 Fantini E, Grynberg A, Athias P, Vilaine JP. Anti-ischaemic drugs: An in vitro study using cultured rat cardiomyocytes. J Mol Cell Cardiol 1992; 24(suppl. VI): xx– xx. 37 Gamier D, Roulet MJ. Vasoactivity of trimetazidine on guinea pig isolated ductus arteriosus. Br J Pharmacol 1985; 84: 517– 524. 38 Gil-Loyzaga P, Simon F, Hernandez E. Trimetazidine protects against cochlear neurotoxicity induced by intraperitoneal administration of kainic acid to the rat. (1994, Personnal Communication). 39 Grynberg A. Regulation of cardiac metabolism at the membrane lipid level. J Mol Cell Cardiol 1997; 29: A33. 40 Guarnieri C, Muscari C. Beneficial effect of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle. Cardiovasc Drugs Ther 1990; 4: 62– 64. 41 Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993; 46: 324– 331. 42 Haguenauer JP. Trimetazidine in degenerative hypoacousis: Effects on hearing and integration. Drugs Today 1990; 26(suppl. 8): 59– 65. 43 Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989; 6: 292– 312. 44 Hauet T, Mothes D, Goujon JM, et al. Trimetazidine prevents renal injury in the isolated perfused pig kidney exposed to prolonged cold ischaemia. Transplantation 1997; 64: 1082– 1086. 45 Hisatome I, Ishiko R, Tanaka Y, et al. Trimetazidine inhibits Na+, K+-ATPase activity, and overdrive hyperpolarization in guinea pig ventricular muscles. Eur J Pharmacol 1991; 195: 381– 388. 46 Honoré E, Adamantidis MM, Challice CE, Dupuis BA. Cardioprotection by calcium antagonists, piridoxilate and trimetazidine. IRCS Med Sci 1986; 14: 938– 939. 47 Hugtenburg JG, Jap TJW, Mathy MJ, et al. Cardioprotective effect of trimetazidine and nifedipine in guinea pig hearts subjected to ischaemia. Arch Int Pharmacodyn Ther 1989; 300: 186– 208. 48 Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: Effects on the energy state and mitochondrial function. Am J Cardiol 1995; 76: 45B– 49B. 49 Kluyskens P, Lambert P, Dhooge D. Trimetazidine versus betahistine in vestibular vertigo. Double-blind study. Drugs Today 1990; 26(suppl. 8): 13– 22. 50 Kober G, Buck I, Sievert H, Vallbracht C. Direct anti-ischemic effect of trimetazidine during coronary angioplasty (PTCA). Circulation 1990; 82: 1119. 51 Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine. Eur Heart J 1992; 13: 1109– 1115. 52 Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97– 110. 53 Libersa C, Honoré E, Adamantidis M, Rouet E, Dupuis B. Anti-ischemic effect of trimetazidine. Enzymatic and electrical response in a model of in vitro myocardial ischemia. Cardiovasc Drugs Ther 1990; 4: 52– 54. 54 Maridonneau-Parini K, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148– 151. 55 Martini A, De Domenico F. Trimetazidine versus betahistine in Meniere's disease. Double-blind study. Drugs Today 1990; 26(suppl. 8): 23– 31. 56 Michaelides AP, Vissoulis GP, Bonoris PE, Psaros TK, Papadopoulos PD, Toutouzas PK. Beneficial effects of trimetazidine in men with stable angina under betablocker treatment. Curr Ther Res 1989; 46: 565– 576. 57 Mody FV, Coyle KB, Hansen HW, et al. A novel metabolically active antianginal agent (trimetazidine) enhances PET-measured glucose utilization. J Mol Cell Cardiol 1997; 29: A32. 58 Morin D, Elimadi A, Sapena R, et al. Evidence for the existence of [3H]trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol 1998; 123: 1385– 1394. 59 Opie LH, Boucher FR. Trimetazidine and myocardial ischemic contracture in isolated rat heart. Am J Cardiol 1995; 76: 38B– 40B. 60 Pech A, Labaeye P, Wayoff M, Lacomme Y, Bebear JP, Morgon A. A 2-month, multicentre, double-blind, placebo-controlled study of trimetazidine in tinnitus. Drugs Today 1990; 26(suppl. 8): 77– 95. 61 Percicot C, Clauser P, Harpey C. Effects of trimetazidine on ocular hypertension. Doc Ophtalmol 1991; 77: 146– 147. 62 Pomin M, Harpey C, Allal PJ, Sellier P, Ourback P. Effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease. J Mol Cell Cardiol 1990; 22(suppl. 22): 150. 63 Rahman F, Toshima Y, Kohno H, Kinoshita K, Tokunaga K. The protective effects of trimetazidine on normothermic ischemic myocardium in rats. Jpn J Surg 1989; 19: 346– 350. 64 Reibel DK, Rovetto MJ. Myocardial ATP synthesis and mechanical function following oxygen deficiency. Am J Physiol 1978; 234: H620– H624. 65 Reymond F, Steyvaert G, Carrupt PA, et al. The pH partition profile of the antiischemic drug trametazidine may explain its reduction of intracellular acidosis. 1998 (submitted). 66 Rochette L, Fitoussi M, Bralet J. Effets du prétraitement par la trimétazidine sur le métabolisme énergétique du coeur isolé de rat soumis à une ligature coronaire et perfusé en normoxie ou en hypoxie. Gaz Med Fr 1984; 91(suppl. 26): 17– 21. 67 Rossi A, Lavanchi N, Martin J. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy study in the isolated rat heart. Cardiovasc Drugs Ther 1990; 4: 812– 813. 68 Roulet MJ, Gamier D. The antianginal drug, trimetazidine, potentiates the tension on hypoxie ductus arteriosus. Inserm 1984; 124: 481– 488. 69 Salducci MD, Chauvet-Monges AM, Tillement JP, et al. Trimetazidine reverses calcium accumulation and impairment of ATP synthesis induced by cyclosporin A in isolated rat liver mitochondria. J Pharmacol Exp Ther 1996; 277: 417– 422. 70 Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem 1997; 175: 153– 162. 71 Settaf A, Lamchouri F, Morin D, Elimadi A, Cherrah Y, Tillement JP. Trimetazidine ameliorates the hepatic injury associated with ischemia-reperfusion in rats. 1998 (submitted). 72 Simon N, Brunet P, Roumenov D, et al. The effects of trimetazidine-cyclosporine A coadministration on interleukin-2, soluble interleukin-2 receptors, and cyclosporine A blood levels in renal transplant patients. Br J Clin Pharmacol 1997; 44: 591– 594. 73 Suàrez-Nieto C, Suarez Garcia MJ, Barthe Garcia P. A comparative study on the effect of various pharmacological agents on the survival of skin flaps in the rat. Br J Plast Surg 1992; 45: 113– 116. 74 Takenaka F, Sakanashi M, Watanabe A, et al. Effects of trimetazidine on the coronary circulation and myocardial metabolism in the dog. Pharmakometrics 1976; 11: 429– 435. 75 Timour Q, Goupit P, Lang J, Durr F, Faucon G. Anti-anginal effects of trimetazidine: Mechanisms. Xth International Congress on Pharmacology. Sydney , Australia , August 2328 1987: 648. 76 Timour Q, Harpey C, Durr F, Faucon G. Is the antianginal action of trimetazidine independent of hemodynamic changes Cardiovasc Drugs Ther 1991; 5: 1043– 1044. 77 Tsimoyiannis EC, Lekkas ET, Paizis JB, Boulis SA, Page P, Kotoulas OB. Prevention of peritoneal adhesions in rats with trimetazidine. Acta Chir Scand 1990; 156: 771– 774. 78 Tsimoyiannis EC, Moutesidou KJ, Moschos CM, Karayianni M, Karkabounas S, Kotoulas OB. Trimetazidine for prevention of hepatic injury induced by ischaemia and reperfusion in rats. Eur J Surg 1993; 159: 89– 93. 79 van Zwieten PA, Hugtenburg JG, Jap TJW, van Heiningen PNM, Bohnenn VA. The cardioprotective effect of trimetazidine and nifedipine in guinea pig hearts subjected to global ischaemia. Br J Pharmacol 1989; 96: 199P. 80 Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828– 833. 81 Zini C, Magnani M, Bortesi G, Bacchus S. La trimétazidine dans certaines affections de l'oreille interne: Étude controlée contre bétahistine. Cah ORL 1997; Hors série: 45– 49. 82 Zini R, Simon N, Morin C, D'Athis P, Tillement JP. Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine. CR Acad Sci Paris 1996; 319: 1087– 1092. 83 Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139– 176. Citing Literature Volume16, Issue4December 1998Pages 359-390 ReferencesRelatedInformation